Bibliography
- MCAULAY V, FRIER B: Insulin analogues and other developments in insulin therapy for diabetes. Expert Opin. Pharmacother. (2003) 4(7):1141–1156.
- HAMANN A, MATTHAEI S, ROSAK C, SILVESTRE L: A randomized, clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with Type 1 diabetes. Diabetes Care (2003) 26(6):1738–1744.
- FANELLI CG, PAMPANELLI S, PORCELLATI F et al.: Pharmacodynamics of subcutaneous injection of insulin glargine after the first as compared to seventh day of its once daily administration in patients with Ti DM. Diabetologia (2002) 45 (Suppl. 2):A258.
- ROSSETTI P, PAMPANELLI S, FANELLI C et al.: Intensive replacement of basal insulin in patients with Type 1 diabetes given rapid-acting insulin analog at mealtime. A 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care (2003) 26(5):1490–1496.
- RIDDLE M, ROSENSTOCK J: Treatment to target in Type 2 diabetes: successful glycaemic control with less nocturnal hypoglycaemia with insulin glargine versus NPH insulin added to oral therapy. Diabetologia (2002) 45\(Suppl. 2):A52.
- ROSENSTOCKJ, MASSI BENEDETTI M, HARING H, LIN Z, SALZMAN A: Confirmed lower risk of hypoglycaemia with insulin glargine versus NPH insulin: a meta-analysis of 2304 patients with Type 2 diabetes. Diabetologia (2003) 46\(Suppl. 2):A304.
- GARG S, HISATOMI M, HOFF H et al: Impact of different insulin glargine regimens on glycemic parameters in intensively treated adults with Type 1 diabetes. Diabetologia (2003) 46\(Suppl. 2):A273.
- KURTZHALS P, SCHAFFER L, SORENSEN A et al.: Correlation of receptor binding and metabolic and mitogenic potencies of insulin analogues designed for clinical use. Diabetes (2000) 49(6):999–1005.
- CIARALDI T, CARTER L, SEIPKE G, MUDALIAR S, HENRY R: Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparison to insulin and IGF-1. Clin. Endocrinol Metab. (2001) 86(12):5838–5847.
- FORJANIC-KLAPPROTH J, HOME PD: Progression of retinopathy with insulin glargine or NPH insulin - a multi-trial analysis. Diabetologia (2001) 44\(Suppl. 1):A287.
- BOLLI GB, OWENS DR: Insulin glargine, a new long-acting insulin analogue soon to be available for the treatment of patients requiring insulin. Lancet (2000) 356(9228):443–445.
- THRAILKILL KM, QUATTRIN T, BAKER L, KUNTZE JE, COMPTON PG, MARTHA PM Jr: Cotherapy with recombinant human insulin-like growth Factor I and insulin improves glycemic control in Type 1 diabetes. RhIGF-I in IDDM Study Group. Diabetes Care (1999) 22(4):585–592.
- LEPORE M, PAMPANELLI S, FANELLI C et al.: Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes (2000) 49(12):2142–2148.
- HEISE T, BOTT S, RAVE K, DRESSLER A,ROSSKAMP R, HEINEMANN L: No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes. Diabet. Med. (2002) 19(6):490–495.
- AMERICAN DIABETES ASSOCIATION: Standards of medical care for patients with diabetes mellitus. ADA position statement. Diabetes Care (2001) 24\(Suppl. 1):S33–S43.
- EUROPEAN DIABETES POLICY GROUP: A desktop guide to Type 2 diabetes mellitus. Diabet. Merl (1999) 16(9):716–730.